Yuvraj_pawp, Author at Pharma Advancement

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

24th October 2015

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of...

Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections

by Yuvraj_pawp

24th October 2015

AstraZeneca today announced positive topline results from RECAPTURE 1 and RECAPTURE 2, the pivotal Phase III studies evaluating the antibiotic,...

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

by Yuvraj_pawp

24th October 2015

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg...

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

by Yuvraj_pawp

24th October 2015

AstraZeneca today announced that its global biologics research and development arm, MedImmune, has entered an agreement granting Daiichi Sankyo Company,...

AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester

by Yuvraj_pawp

24th October 2015

AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients....

AstraZeneca purchases US biologics manufacturing facility to support growing pipeline

by Yuvraj_pawp

24th October 2015

AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing...

Immuno-oncology: an update on progress at the European Cancer Congress

by Yuvraj_pawp

24th October 2015

Within the rapidly evolving world of cancer treatment and the excitement surrounding immuno-oncology, it is more important than ever to...

AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)

by Yuvraj_pawp

24th October 2015

AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research...

Guangzhou Medical University & AstraZeneca: Advancing understanding of COPD in China

by Yuvraj_pawp

24th October 2015

We’re working with Guangzhou Medical University, one of the world’s leading centres for research into respiratory disease, to advance the...

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis

by Yuvraj_pawp

24th October 2015

The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and...

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Yuvraj_pawp

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections

US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack

AstraZeneca enters license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan

AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester

AstraZeneca purchases US biologics manufacturing facility to support growing pipeline

Immuno-oncology: an update on progress at the European Cancer Congress

AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)

Guangzhou Medical University & AstraZeneca: Advancing understanding of COPD in China

New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis

Qucik Links

About Us

Subscribe Us

System

Resources

Retrieve your password